Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone nasal spray for gambling disorder
2017-001946-93Phase 2Completed
- Sponsor
- Finnish Institute for Health and Welfare
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gambling disorder (GD) comparing Naloxone nasal spray with Placebo nasal spray (2 arms). Primary endpoint: Change in gambling symptoms (G-SAS). Started Oct 2017; status: completed.
02
Drugs
naloxone
03
Conditions
gambling disorder (GD)
Beyond the preview
Go deeper on 2017-001946-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001946-93.